49 results on '"Manoela Tiago"'
Search Results
2. Co-Targeting FASN and mTOR Suppresses Uveal Melanoma Growth
- Author
-
Anna Han, Dzmitry Mukha, Vivian Chua, Timothy J. Purwin, Manoela Tiago, Bhavik Modasia, Usman Baqai, Jenna L. Aumiller, Nelisa Bechtel, Emily Hunter, Meggie Danielson, Mizue Terai, Philip B. Wedegaertner, Takami Sato, Solange Landreville, Michael A. Davies, Stefan Kurtenbach, J. William Harbour, Zachary T. Schug, and Andrew E. Aplin
- Subjects
fatty acid synthase ,mTOR pathway ,metabolic inhibition ,uveal melanoma ,GNAQ ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Uveal melanoma (UM) displays a high frequency of metastasis; however, effective therapies for metastatic UM are limited. Identifying unique metabolic features of UM may provide a potential targeting strategy. A lipid metabolism protein expression signature was induced in a normal choroidal melanocyte (NCM) line transduced with GNAQ (Q209L), a driver in UM growth and development. Consistently, UM cells expressed elevated levels of fatty acid synthase (FASN) compared to NCMs. FASN upregulation was associated with increased mammalian target of rapamycin (mTOR) activation and sterol regulatory element-binding protein 1 (SREBP1) levels. FASN and mTOR inhibitors alone significantly reduced UM cell growth. Concurrent inhibition of FASN and mTOR further reduced UM cell growth by promoting cell cycle arrest and inhibiting glucose utilization, TCA cycle metabolism, and de novo fatty acid biosynthesis. Our findings indicate that FASN is important for UM cell growth and co-inhibition of FASN and mTOR signaling may be considered for treatment of UM.
- Published
- 2023
- Full Text
- View/download PDF
3. A natural bacterial-derived product, the metalloprotease arazyme, inhibits metastatic murine melanoma by inducing MMP-8 cross-reactive antibodies.
- Author
-
Felipe V Pereira, Carla A Ferreira-Guimarães, Thaysa Paschoalin, Jorge A B Scutti, Filipe M Melo, Luis S Silva, Amanda C L Melo, Priscila Silva, Manoela Tiago, Alisson L Matsuo, Luiz Juliano, Maria A Juliano, Adriana K Carmona, Luiz R Travassos, and Elaine G Rodrigues
- Subjects
Medicine ,Science - Abstract
The increased incidence, high rates of mortality and few effective means of treatment of malignant melanoma, stimulate the search for new anti-tumor agents and therapeutic targets to control this deadly metastatic disease. In the present work the antitumor effect of arazyme, a natural bacterial-derived metalloprotease secreted by Serratia proteomaculans, was investigated. Arazyme significantly reduced the number of pulmonary metastatic nodules after intravenous inoculation of B16F10 melanoma cells in syngeneic mice. In vitro, the enzyme showed a dose-dependent cytostatic effect in human and murine tumor cells, and this effect was associated to the proteolytic activity of arazyme, reducing the CD44 expression at the cell surface, and also reducing in vitro adhesion and in vitro/in vivo invasion of these cells. Arazyme treatment or immunization induced the production of protease-specific IgG that cross-reacted with melanoma MMP-8. In vitro, this antibody was cytotoxic to tumor cells, an effect increased by complement. In vivo, arazyme-specific IgG inhibited melanoma lung metastasis. We suggest that the antitumor activity of arazyme in a preclinical model may be due to a direct cytostatic activity of the protease in combination with the elicited anti-protease antibody, which cross-reacts with MMP-8 produced by tumor cells. Our results show that the bacterial metalloprotease arazyme is a promising novel antitumor chemotherapeutic agent.
- Published
- 2014
- Full Text
- View/download PDF
4. Apoptosis through Bcl-2/Bax and cleaved caspase up-regulation in melanoma treated by boron neutron capture therapy.
- Author
-
Fernanda Faião-Flores, Paulo Rogério Pinto Coelho, João Dias Toledo Arruda-Neto, Silvya Stuchi Maria-Engler, Manoela Tiago, Vera Luiza Capelozzi, Ricardo Rodrigues Giorgi, and Durvanei Augusto Maria
- Subjects
Medicine ,Science - Abstract
Boron neutron capture therapy (BNCT) is a binary treatment involving selective accumulation of boron carriers in a tumor followed by irradiation with a thermal or epithermal neutron beam. The neutron capture reaction with a boron-10 nucleus yields high linear energy transfer (LET) particles, alpha and (7)Li, with a range of 5 to 9 µm. These particles can only travel very short distances and release their damaging energy directly into the cells containing the boron compound. We aimed to evaluate proliferation, apoptosis and extracellular matrix (ECM) modifications of B16F10 melanoma and normal human melanocytes after BNCT. The amounts of soluble collagen and Hsp47, indicating collagen synthesis in the ECM, as well as the cellular markers of apoptosis, were investigated. BNCT decreased proliferation, altered the ECM by decreasing collagen synthesis and induced apoptosis by regulating Bcl-2/Bax in melanoma. Additionally, BNCT also increased the levels of TNF receptor and the cleaved caspases 3, 7, 8 and 9 in melanoma. These results suggest that multiple pathways related to cell death and cell cycle arrest are involved in the treatment of melanoma by BNCT.
- Published
- 2013
- Full Text
- View/download PDF
5. Raptinal Induces Gasdermin E–Dependent Pyroptosis in Naïve and Therapy-Resistant Melanoma
- Author
-
Megane Vernon, Nicole A. Wilski, Daniel Kotas, Weijia Cai, Danielle Pomante, Manoela Tiago, Emad S. Alnemri, and Andrew E. Aplin
- Subjects
Mice ,Cancer Research ,Oncology ,Pyroptosis ,Animals ,Humans ,Cytokines ,Cyclopentanes ,Melanoma ,Molecular Biology ,Article - Abstract
Lack of response and acquired resistance continue to be limitations of targeted and immune-based therapies. Pyroptosis is an inflammatory form of cell death characterized by the release of inflammatory damage-associated molecular patterns (DAMP) and cytokines via gasdermin (GSDM) protein pores in the plasma membrane. Induction of pyroptosis has implications for treatment strategies in both therapy-responsive, as well as resistance forms of melanoma. We show that the caspase-3 activator, raptinal, induces pyroptosis in both human and mouse melanoma cell line models and delays tumor growth in vivo. Release of DAMPs and inflammatory cytokines was dependent on caspase activity and GSDME expression. Furthermore, raptinal stimulated pyroptosis in melanoma models that have acquired resistance to BRAF and MEK inhibitor therapy. These findings add support to efforts to induce pyroptosis in both the treatment-naïve and resistant settings. Implications: Raptinal can rapidly induce pyroptosis in naïve and BRAFi plus MEKi-resistant melanoma, which may be beneficial for patients who have developed acquired resistance to targeted therapies.
- Published
- 2022
6. Co-Targeting FASN and mTOR Suppresses Uveal Melanoma Growth
- Author
-
Aplin, Anna Han, Dzmitry Mukha, Vivian Chua, Timothy J. Purwin, Manoela Tiago, Bhavik Modasia, Usman Baqai, Jenna L. Aumiller, Nelisa Bechtel, Emily Hunter, Meggie Danielson, Mizue Terai, Philip B. Wedegaertner, Takami Sato, Solange Landreville, Michael A. Davies, Stefan Kurtenbach, J. William Harbour, Zachary T. Schug, and Andrew E.
- Subjects
fatty acid synthase ,mTOR pathway ,metabolic inhibition ,uveal melanoma ,GNAQ - Abstract
Uveal melanoma (UM) displays a high frequency of metastasis; however, effective therapies for metastatic UM are limited. Identifying unique metabolic features of UM may provide a potential targeting strategy. A lipid metabolism protein expression signature was induced in a normal choroidal melanocyte (NCM) line transduced with GNAQ (Q209L), a driver in UM growth and development. Consistently, UM cells expressed elevated levels of fatty acid synthase (FASN) compared to NCMs. FASN upregulation was associated with increased mammalian target of rapamycin (mTOR) activation and sterol regulatory element-binding protein 1 (SREBP1) levels. FASN and mTOR inhibitors alone significantly reduced UM cell growth. Concurrent inhibition of FASN and mTOR further reduced UM cell growth by promoting cell cycle arrest and inhibiting glucose utilization, TCA cycle metabolism, and de novo fatty acid biosynthesis. Our findings indicate that FASN is important for UM cell growth and co-inhibition of FASN and mTOR signaling may be considered for treatment of UM.
- Published
- 2023
- Full Text
- View/download PDF
7. Supplementary Figures from Activation of CD8+ T Cells Contributes to Antitumor Effects of CDK4/6 Inhibitors plus MEK Inhibitors
- Author
-
Andrew E. Aplin, Reinhard Dummer, Xiaowei Xu, Mitch P. Levesque, Inna Chervoneva, Conroy O. Field, Nicole A. Wilski, Manoela Tiago, Phil F. Cheng, Dan A. Erkes, and Jessica L.F. Teh
- Abstract
Supplementary Figures
- Published
- 2023
8. Supplementary Figure Legends from Activation of CD8+ T Cells Contributes to Antitumor Effects of CDK4/6 Inhibitors plus MEK Inhibitors
- Author
-
Andrew E. Aplin, Reinhard Dummer, Xiaowei Xu, Mitch P. Levesque, Inna Chervoneva, Conroy O. Field, Nicole A. Wilski, Manoela Tiago, Phil F. Cheng, Dan A. Erkes, and Jessica L.F. Teh
- Abstract
Supplementary Figure Legends
- Published
- 2023
9. Data from Activation of CD8+ T Cells Contributes to Antitumor Effects of CDK4/6 Inhibitors plus MEK Inhibitors
- Author
-
Andrew E. Aplin, Reinhard Dummer, Xiaowei Xu, Mitch P. Levesque, Inna Chervoneva, Conroy O. Field, Nicole A. Wilski, Manoela Tiago, Phil F. Cheng, Dan A. Erkes, and Jessica L.F. Teh
- Abstract
Concurrent MEK and CDK4/6 inhibition shows promise in clinical trials for patients with advanced-stage mutant BRAF/NRAS solid tumors. The effects of CDK4/6 inhibitor (CDK4/6i) in combination with BRAF/MEK-targeting agents on the tumor immune microenvironment are unclear, especially in melanoma, for which immune checkpoint inhibitors are effective in approximately 50% of patients. Here, we show that patients progressing on CDK4/6i/MEK pathway inhibitor combinations exhibit T-cell exclusion. We found that MEK and CDK4/6 targeting was more effective at delaying regrowth of mutant BRAF melanoma in immunocompetent versus immune-deficient mice. Although MEK inhibitor (MEKi) treatment increased tumor immunogenicity and intratumoral recruitment of CD8+ T cells, the main effect of CDK4/6i alone and in combination with MEKi was increased expression of CD137L, a T-cell costimulatory molecule on immune cells. Depletion of CD8+ T cells or blockade of the CD137 ligand–receptor interaction reduced time to regrowth of melanomas in the context of treatment with CDK4/6i plus MEKi treatment in vivo. Together, our data outline an antitumor immune-based mechanism and show the efficacy of targeting both the MEK pathway and CDK4/6.
- Published
- 2023
10. Supplementary Figure from Raptinal Induces Gasdermin E–Dependent Pyroptosis in Naïve and Therapy-Resistant Melanoma
- Author
-
Andrew E. Aplin, Emad S. Alnemri, Manoela Tiago, Danielle Pomante, Weijia Cai, Daniel Kotas, Nicole A. Wilski, and Megane Vernon
- Abstract
Supplementary Figure from Raptinal Induces Gasdermin E–Dependent Pyroptosis in Naïve and Therapy-Resistant Melanoma
- Published
- 2023
11. Supplementary Fig 4 from Synthetic Lethal Screens Reveal Cotargeting FAK and MEK as a Multimodal Precision Therapy for GNAQ-Driven Uveal Melanoma
- Author
-
J. Silvio Gutkind, Andrew E. Aplin, Takami Sato, Jonathan A. Pachter, Prashant Mali, Glenn Merlino, Chi-Ping Day, Kyle Ford, Xingyu Wu, Silvia Coma, Manoela Tiago, Nadia Arang, Frederico Gomes, Simone Lubrano, Ayush Kishore, Robert Saddawi-Konefka, Monica Acosta, and Justine S. Paradis
- Abstract
Supplementary Figure S4. MEKi/FAKi combination reduces B2905 syngeneic cells growth in allograft tumor models.
- Published
- 2023
12. Data from Synthetic Lethal Screens Reveal Cotargeting FAK and MEK as a Multimodal Precision Therapy for GNAQ-Driven Uveal Melanoma
- Author
-
J. Silvio Gutkind, Andrew E. Aplin, Takami Sato, Jonathan A. Pachter, Prashant Mali, Glenn Merlino, Chi-Ping Day, Kyle Ford, Xingyu Wu, Silvia Coma, Manoela Tiago, Nadia Arang, Frederico Gomes, Simone Lubrano, Ayush Kishore, Robert Saddawi-Konefka, Monica Acosta, and Justine S. Paradis
- Abstract
Purpose:Uveal melanoma is the most common eye cancer in adults. Approximately 50% of patients with uveal melanoma develop metastatic uveal melanoma (mUM) in the liver, even after successful treatment of the primary lesions. mUM is refractory to current chemo- and immune-therapies, and most mUM patients die within a year. Uveal melanoma is characterized by gain-of-function mutations in GNAQ/GNA11, encoding Gαq proteins. We have recently shown that the Gαq–oncogenic signaling circuitry involves a noncanonical pathway distinct from the classical activation of PLCβ and MEK–ERK. GNAQ promotes the activation of YAP1, a key oncogenic driver, through focal adhesion kinase (FAK), thereby identifying FAK as a druggable signaling hub downstream from GNAQ. However, targeted therapies often activate compensatory resistance mechanisms leading to cancer relapse and treatment failure.Experimental Design:We performed a kinome-wide CRISPR-Cas9 sgRNA screen to identify synthetic lethal gene interactions that can be exploited therapeutically. Candidate adaptive resistance mechanisms were investigated by cotargeting strategies in uveal melanoma and mUM in vitro and in vivo experimental systems.Results:sgRNAs targeting the PKC and MEK–ERK signaling pathways were significantly depleted after FAK inhibition, with ERK activation representing a predominant resistance mechanism. Pharmacologic inhibition of MEK and FAK showed remarkable synergistic growth-inhibitory effects in uveal melanoma cells and exerted cytotoxic effects, leading to tumor collapse in uveal melanoma xenograft and liver mUM models in vivo.Conclusions:Coupling the unique genetic landscape of uveal melanoma with the power of unbiased genetic screens, our studies reveal that FAK and MEK–ERK cotargeting may provide a new network-based precision therapeutic strategy for mUM treatment.See related commentary by Harbour, p. 2967
- Published
- 2023
13. Supplementary Fig 2 from Synthetic Lethal Screens Reveal Cotargeting FAK and MEK as a Multimodal Precision Therapy for GNAQ-Driven Uveal Melanoma
- Author
-
J. Silvio Gutkind, Andrew E. Aplin, Takami Sato, Jonathan A. Pachter, Prashant Mali, Glenn Merlino, Chi-Ping Day, Kyle Ford, Xingyu Wu, Silvia Coma, Manoela Tiago, Nadia Arang, Frederico Gomes, Simone Lubrano, Ayush Kishore, Robert Saddawi-Konefka, Monica Acosta, and Justine S. Paradis
- Abstract
Supplementary figure S2. Isobologram analysis.
- Published
- 2023
14. Supplementary Fig 1 from Synthetic Lethal Screens Reveal Cotargeting FAK and MEK as a Multimodal Precision Therapy for GNAQ-Driven Uveal Melanoma
- Author
-
J. Silvio Gutkind, Andrew E. Aplin, Takami Sato, Jonathan A. Pachter, Prashant Mali, Glenn Merlino, Chi-Ping Day, Kyle Ford, Xingyu Wu, Silvia Coma, Manoela Tiago, Nadia Arang, Frederico Gomes, Simone Lubrano, Ayush Kishore, Robert Saddawi-Konefka, Monica Acosta, and Justine S. Paradis
- Abstract
Supplementary figure S1. Synthetic lethality of FAK and ERK/MAPK pathway inhibition.
- Published
- 2023
15. Supplementary Fig 3 from Synthetic Lethal Screens Reveal Cotargeting FAK and MEK as a Multimodal Precision Therapy for GNAQ-Driven Uveal Melanoma
- Author
-
J. Silvio Gutkind, Andrew E. Aplin, Takami Sato, Jonathan A. Pachter, Prashant Mali, Glenn Merlino, Chi-Ping Day, Kyle Ford, Xingyu Wu, Silvia Coma, Manoela Tiago, Nadia Arang, Frederico Gomes, Simone Lubrano, Ayush Kishore, Robert Saddawi-Konefka, Monica Acosta, and Justine S. Paradis
- Abstract
Supplementary figure 3. MEKi/FAKi combination reduces UM cells growth in xenograft tumor models with limited toxicity.
- Published
- 2023
16. A Genome-wide screen identifies PDPK1 as a target to enhance the efficacy of MEK1/2 inhibitors in NRAS mutant melanoma
- Author
-
Weijia Cai, Mai Q. Nguyen, Nicole A. Wilski, Timothy J. Purwin, Mégane Vernon, Manoela Tiago, and Andrew E. Aplin
- Subjects
Mitogen-Activated Protein Kinase Kinases ,Proto-Oncogene Proteins B-raf ,Cancer Research ,MAP Kinase Kinase 2 ,MAP Kinase Kinase 1 ,Membrane Proteins ,Article ,GTP Phosphohydrolases ,3-Phosphoinositide-Dependent Protein Kinases ,Mice ,Oncology ,Cell Line, Tumor ,Mutation ,Animals ,Humans ,1-Phosphatidylinositol 4-Kinase ,Melanoma ,Protein Kinase Inhibitors - Abstract
Melanomas frequently harbor activating NRAS mutations. However, limited advance has been made in developing targeted therapy options for patients with NRAS mutant melanoma. MEK inhibitors (MEKi) show modest efficacy in the clinic and their actions need to be optimized. In this study, we performed a genome-wide CRISPR-Cas9–based screen and demonstrated that loss of phosphoinositide-dependent kinase-1 (PDPK1) enhances the efficacy of MEKi. The synergistic effects of PDPK1 loss and MEKi was validated in NRAS mutant melanoma cell lines using pharmacologic and molecular approaches. Combined PDPK1 inhibitors (PDPK1i) with MEKi suppressed NRAS mutant xenograft growth and induced gasdermin E–associated pyroptosis. In an immune-competent allograft model, PDPK1i+MEKi increased the ratio of intratumoral CD8+ T cells, delayed tumor growth, and prolonged survival; the combination treatment was less effective against tumors in immune-deficient mice. These data suggest PDPK1i+MEKi as an efficient immunostimulatory strategy against NRAS mutant melanoma. Significance: Targeting PDPK1 stimulates antitumor immunity and sensitizes NRAS mutant melanoma to MEK inhibition, providing rationale for the clinical development of a combinatorial approach for treating patients with melanoma.
- Published
- 2022
17. Synthetic Lethal Screens Reveal Cotargeting FAK and MEK as a Multimodal Precision Therapy forGNAQ-Driven Uveal Melanoma
- Author
-
Andrew E. Aplin, Justine S. Paradis, J. Silvio Gutkind, Prashant Mali, Manoela Tiago, Robert Saddawi-Konefka, Monica Acosta, Xingyu Wu, Glenn Merlino, Chi-Ping Day, Nadia Arang, Takami Sato, Silvia Coma, Simone Lubrano, Jonathan A. Pachter, Kyle Ford, Frederico Gomes, and Ayush Kishore
- Subjects
0301 basic medicine ,YAP1 ,MAPK/ERK pathway ,Cancer Research ,GNA11 ,business.industry ,Melanoma ,Cancer ,medicine.disease ,03 medical and health sciences ,030104 developmental biology ,0302 clinical medicine ,Oncology ,030220 oncology & carcinogenesis ,medicine ,Cancer research ,Signal transduction ,business ,GNAQ ,Genetic screen - Abstract
Purpose:Uveal melanoma is the most common eye cancer in adults. Approximately 50% of patients with uveal melanoma develop metastatic uveal melanoma (mUM) in the liver, even after successful treatment of the primary lesions. mUM is refractory to current chemo- and immune-therapies, and most mUM patients die within a year. Uveal melanoma is characterized by gain-of-function mutations in GNAQ/GNA11, encoding Gαq proteins. We have recently shown that the Gαq–oncogenic signaling circuitry involves a noncanonical pathway distinct from the classical activation of PLCβ and MEK–ERK. GNAQ promotes the activation of YAP1, a key oncogenic driver, through focal adhesion kinase (FAK), thereby identifying FAK as a druggable signaling hub downstream from GNAQ. However, targeted therapies often activate compensatory resistance mechanisms leading to cancer relapse and treatment failure.Experimental Design:We performed a kinome-wide CRISPR-Cas9 sgRNA screen to identify synthetic lethal gene interactions that can be exploited therapeutically. Candidate adaptive resistance mechanisms were investigated by cotargeting strategies in uveal melanoma and mUM in vitro and in vivo experimental systems.Results:sgRNAs targeting the PKC and MEK–ERK signaling pathways were significantly depleted after FAK inhibition, with ERK activation representing a predominant resistance mechanism. Pharmacologic inhibition of MEK and FAK showed remarkable synergistic growth-inhibitory effects in uveal melanoma cells and exerted cytotoxic effects, leading to tumor collapse in uveal melanoma xenograft and liver mUM models in vivo.Conclusions:Coupling the unique genetic landscape of uveal melanoma with the power of unbiased genetic screens, our studies reveal that FAK and MEK–ERK cotargeting may provide a new network-based precision therapeutic strategy for mUM treatment.See related commentary by Harbour, p. 2967
- Published
- 2021
18. Abstract A005: The aged tumor microenvironment influences tolerance to targeted therapy via NR2F1 overexpression in BRAF-mutant melanoma
- Author
-
Manoela Tiago, Timothy J. Purwin, Mitchell E. Fane, Yash Chhabra, Jessica L. F. Teh, Rama Kadamb, Weijia Cai, Inna Chervoneva, Sheera Rosenbaum, Vivian Chua, Nir Hacohen, Michael A. Davies, Jessie Villanieva, Ashani T. Weeraratna, Claudia Capparelli, Julio A. Aguirre-Ghiso, and Andrew E. Aplin
- Subjects
Cancer Research ,Oncology - Abstract
Despite the clinical success of targeted inhibitors, tumor responses to these agents are transient, and drug-tolerant residual cells seed resistance. Understanding the role of tumor-intrinsic mechanisms and effects of the tumor microenvironment in mediating drug tolerance will guide and optimize targeted therapies. Given similarities between drug tolerance and cellular dormancy, we studied the role of nuclear receptor subfamily 2 group F member 1 (NR2F1) in response to targeted therapy. We used BRAF-mutant cutaneous melanoma models treated with BRAF and MEK inhibitors (BRAFi + MEKi) since patients treated with this combination typically develop resistance. The aged tumor microenvironment has been shown to increase therapy resistance, and we find that melanoma cells in aged mice express higher levels of NR2F1 than when the same cells are injected into young animals. Transcriptomic analysis of melanoma patient samples treated with BRAFi + MEKi showed increased expression of NR2F1 post-treatment. Similarly, NR2F1 was highly expressed in minimal residual disease collected on BRAFi + MEKi treatment in patient- and xenograft-derived tumors. High expression of NR2F1 promotes tumor survival and invasion in the presence of BRAFi + MEKi in vitro leading to tolerance to BRAFi + MEKi efficacy in vivo. Depletion of NR2F1 in YUMM1.7 allografts grown in aged mice improved response to the combination therapy. Altogether, our findings suggest that NR2F1 promotes drug tolerance leading to minimal residual disease in melanoma and that NR2F1-high cells may be targeted with CDK4/6 inhibitors to improve targeted therapy outcomes in melanoma patients. Citation Format: Manoela Tiago, Timothy J. Purwin, Mitchell E. Fane, Yash Chhabra, Jessica L. F. Teh, Rama Kadamb, Weijia Cai, Inna Chervoneva, Sheera Rosenbaum, Vivian Chua, Nir Hacohen, Michael A. Davies, Jessie Villanieva, Ashani T. Weeraratna, Claudia Capparelli, Julio A. Aguirre-Ghiso, Andrew E. Aplin. The aged tumor microenvironment influences tolerance to targeted therapy via NR2F1 overexpression in BRAF-mutant melanoma [abstract]. In: Proceedings of the AACR Special Conference: Aging and Cancer; 2022 Nov 17-20; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2022;83(2 Suppl_1):Abstract nr A005.
- Published
- 2023
19. Melatonin inhibits human melanoma cells proliferation and invasion via cell cycle arrest and cytoskeleton remodeling
- Author
-
Renata de Freitas Saito, Silvya Stuchi Maria-Engler, Maria S. Soengas, Patrícia da Cruz Souza, Renato Ramos Massaro, Roberta Liberato Pagni, Russel J. Reiter, Ana Carolina Ramos Moreno, Ana Campa, Manoela Tiago, and Rafael Pegoraro
- Subjects
Cell cycle checkpoint ,Melanoma ,Cancer ,Context (language use) ,Biology ,Cell cycle ,medicine.disease ,Melatonin ,Downregulation and upregulation ,medicine ,Cancer research ,Clonogenic assay ,CICLO CELULAR ,medicine.drug - Abstract
Among skin cancers, melanoma has the highest mortality rate. The heterogeneous genetic melanoma background leads to a tumor-propagating capacity particularly important in maintaining therapeutic resistance, and tumor recurrence. The identification of efficient molecules able to control melanoma progress represents an important opportunity for new therapeutic strategies, particularly in combination with the current standard-of-care treatments. In this context, several studies have reported the antitumor effects of melatonin against different types of cancer, including melanoma. Here, we describe the underlying mechanisms associated with melatonin’s activity in human melanoma cell lines, focusing on cell cycle and cytoskeleton remodeling. Interestingly, while melatonin induced melanocyte DNA replication, melanoma cells exhibited cell cycle arrest in the G1-phase. This phenomenon was associated with cyclin-D1 downregulation or p21 overexpression. The efficacy of melatonin on melanoma cells survival and proliferation was detected using the clonogenic assay, with a decrease in both the number and size of colonies. Additionally, melatonin induced a dramatic cytoskeleton remodeling in all melanoma cell lines, leading to a star-like morphology or cell swelling. The role of melatonin on melanoma cytoskeleton was associated with the actin disruption, with thinning and/or broken actin fibers, and weak and/or loss of paxillin along stress fibers. These data support the observed findings that melatonin impairs melanoma invasion in skin reconstructed models. Together, our results suggest that melatonin could be used to control melanoma growth and support basic and clinical studies on melatonin as a promising immunometabolic adjuvant for melanoma therapy.
- Published
- 2020
20. Targeting SOX10-deficient cells to reduce the dormant-invasive phenotype state in melanoma
- Author
-
Claudia, Capparelli, Timothy J, Purwin, McKenna, Glasheen, Signe, Caksa, Manoela, Tiago, Nicole, Wilski, Danielle, Pomante, Sheera, Rosenbaum, Mai Q, Nguyen, Weijia, Cai, Janusz, Franco-Barraza, Richard, Zheng, Gaurav, Kumar, Inna, Chervoneva, Ayako, Shimada, Vito W, Rebecca, Adam E, Snook, Kim, Hookim, Xiaowei, Xu, Edna, Cukierman, Meenhard, Herlyn, and Andrew E, Aplin
- Subjects
Proto-Oncogene Proteins B-raf ,Phenotype ,Skin Neoplasms ,SOXE Transcription Factors ,Cell Line, Tumor ,Tumor Microenvironment ,Humans ,Melanoma - Abstract
Cellular plasticity contributes to intra-tumoral heterogeneity and phenotype switching, which enable adaptation to metastatic microenvironments and resistance to therapies. Mechanisms underlying tumor cell plasticity remain poorly understood. SOX10, a neural crest lineage transcription factor, is heterogeneously expressed in melanomas. Loss of SOX10 reduces proliferation, leads to invasive properties, including the expression of mesenchymal genes and extracellular matrix, and promotes tolerance to BRAF and/or MEK inhibitors. We identify the class of cellular inhibitor of apoptosis protein-1/2 (cIAP1/2) inhibitors as inducing cell death selectively in SOX10-deficient cells. Targeted therapy selects for SOX10 knockout cells underscoring their drug tolerant properties. Combining cIAP1/2 inhibitor with BRAF/MEK inhibitors delays the onset of acquired resistance in melanomas in vivo. These data suggest that SOX10 mediates phenotypic switching in cutaneous melanoma to produce a targeted inhibitor tolerant state that is likely a prelude to the acquisition of resistance. Furthermore, we provide a therapeutic strategy to selectively eliminate SOX10-deficient cells.
- Published
- 2021
21. Pyruvate dehydrogenase inactivation causes glycolytic phenotype in BAP1 mutant uveal melanoma
- Author
-
Anna Han, Vivian Chua, Usman Baqai, Timothy J. Purwin, Nelisa Bechtel, Emily Hunter, Manoela Tiago, Erin Seifert, David W. Speicher, Zachary T. Schug, J. William Harbour, and Andrew E. Aplin
- Subjects
Uveal Neoplasms ,Cancer Research ,Genetics ,Molecular Biology ,Melanoma ,Article - Abstract
Effective therapeutic options are still lacking for uveal melanoma (UM) patients who develop metastasis. Metastatic traits of UM are linked to BRCA1-associated protein 1 (BAP1) mutations. Cell metabolism is re-programmed in UM with BAP1 mutant UM, but the underlying mechanisms and opportunities for therapeutic intervention remain unclear. BAP1 mutant UM tumors have an elevated glycolytic gene expression signature, with increased expression of pyruvate dehydrogenase (PDH) complex and PDH kinase (PDHK1). Furthermore, BAP1 mutant UM cells showed higher levels of phosphorylated PDHK1 and PDH that was associated with an upregulated glycolytic profile compared to BAP1 wild type UM cells. Suppressing PDHK1-PDH phosphorylation decreased glycolytic capacity and cell growth, and induced cell cycle arrest of BAP1 mutant UM cells. Our results suggest that PDHK1-PDH phosphorylation is a causative factor of glycolytic phenotypes found in BAP1 mutant UM and propose a therapeutic opportunity for BAP1 mutant UM patients.
- Published
- 2021
22. Synthetic Lethal Screens Reveal Cotargeting FAK and MEK as a Multimodal Precision Therapy for
- Author
-
Justine S, Paradis, Monica, Acosta, Robert, Saddawi-Konefka, Ayush, Kishore, Frederico, Gomes, Nadia, Arang, Manoela, Tiago, Silvia, Coma, Simone, Lubrano, Xingyu, Wu, Kyle, Ford, Chi-Ping, Day, Glenn, Merlino, Prashant, Mali, Jonathan A, Pachter, Takami, Sato, Andrew E, Aplin, and J Silvio, Gutkind
- Subjects
Uveal Neoplasms ,MAP Kinase Signaling System ,Mice, SCID ,Combined Modality Therapy ,Xenograft Model Antitumor Assays ,HEK293 Cells ,Mice, Inbred NOD ,Focal Adhesion Kinase 1 ,Gain of Function Mutation ,Animals ,GTP-Binding Protein alpha Subunits, Gq-G11 ,Humans ,Female ,Genetic Testing ,Molecular Targeted Therapy ,Melanoma - Abstract
Uveal melanoma is the most common eye cancer in adults. Approximately 50% of patients with uveal melanoma develop metastatic uveal melanoma (mUM) in the liver, even after successful treatment of the primary lesions. mUM is refractory to current chemo- and immune-therapies, and most mUM patients die within a year. Uveal melanoma is characterized by gain-of-function mutations inWe performed a kinome-wide CRISPR-Cas9 sgRNA screen to identify synthetic lethal gene interactions that can be exploited therapeutically. Candidate adaptive resistance mechanisms were investigated by cotargeting strategies in uveal melanoma and mUMsgRNAs targeting the PKC and MEK-ERK signaling pathways were significantly depleted after FAK inhibition, with ERK activation representing a predominant resistance mechanism. Pharmacologic inhibition of MEK and FAK showed remarkable synergistic growth-inhibitory effects in uveal melanoma cells and exerted cytotoxic effects, leading to tumor collapse in uveal melanoma xenograft and liver mUM modelsCoupling the unique genetic landscape of uveal melanoma with the power of unbiased genetic screens, our studies reveal that FAK and MEK-ERK cotargeting may provide a new network-based precision therapeutic strategy for mUM treatment.
- Published
- 2020
23. Activation of CD8
- Author
-
Jessica L F, Teh, Dan A, Erkes, Phil F, Cheng, Manoela, Tiago, Nicole A, Wilski, Conroy O, Field, Inna, Chervoneva, Mitch P, Levesque, Xiaowei, Xu, Reinhard, Dummer, and Andrew E, Aplin
- Subjects
Male ,Aniline Compounds ,integumentary system ,endocrine system diseases ,Acrylonitrile ,Cyclin-Dependent Kinase 4 ,Cyclin-Dependent Kinase 6 ,CD8-Positive T-Lymphocytes ,Article ,enzymes and coenzymes (carbohydrates) ,Mice ,Animals ,Humans ,biological phenomena, cell phenomena, and immunity ,neoplasms - Abstract
Concurrent MEK and CDK4/6 inhibition shows promise in clinical trials for patients with advanced-stage mutant BRAF/NRAS solid tumors. The effects of CDK4/6 inhibitor (CDK4/6i) in combination with BRAF/MEK targeting agents on the tumor immune microenvironment are unclear, especially in melanoma for which immune checkpoint inhibitors are effective in ~50% of patients. Here, we show that patients progressing on the CDK4/6i/MEK pathway inhibitor combinations showed T-cell exclusion. We found that MEK and CDK4/6 targeting was more effective at delaying regrowth of mutant BRAF melanoma in immune-competent versus immune-deficient mice. Although MEK inhibitor (MEKi) treatment increased tumor immunogenicity and intra-tumoral recruitment of CD8(+) T cells, the main effect of CDK4/6i alone and in combination with MEKi was increased expression of CD137L, a T-cell costimulatory molecule on immune cells. Depletion of CD8(+) T cells or blockade of the CD137 ligand-receptor interaction reduced time to regrowth of melanomas in the context of treatment with CDK4/6i plus MEKi treatment in vivo. Together, our data outline an antitumor immune-based mechanism and show the efficacy of targeting both the MEK pathway and CDK4/6.
- Published
- 2019
24. Connections of annexin A1 and translocator protein-18 kDa on toll like receptor stimulated BV-2 cells
- Author
-
Lorena do Nascimento Pantaleão, Manoela Tiago, Silvya Stucchi Maria-Engler, Egle Solito, Sandra Helena Poliselli Farsky, Chris P. M. Reutelingsperger, Gustavo Henrique Oliveira da Rocha, Pantaleao, L., Rocha, G. H. O., Reutelingsperger, C., GOMES PEREIRA, Tiago, Maria-Engler, S. S., Solito, E., Farsky, S. P., Biochemie, and RS: CARIM - R1.02 - Vascular aspects thrombosis and haemostasis
- Subjects
Lipopolysaccharides ,0301 basic medicine ,DISRUPTION ,NF-κB ,PATHWAY ,Mice ,0302 clinical medicine ,TNFα ,IN-VIVO ,Annexin A1 ,Toll-like receptor ,biology ,Microglia ,NF-kappa B ,Cell biology ,medicine.anatomical_structure ,Cytokines ,Tumor necrosis factor alpha ,Human ,Signal Transduction ,FPR2 ,LPS ,INHIBITION ,Lipopolysaccharide ,Formyl peptide receptor 2 ,Cell Line ,NEUROINFLAMMATION ,03 medical and health sciences ,Receptors, GABA ,INFLAMMATION ,Translocator protein ,medicine ,Animals ,Humans ,Cytokine ,Neuroinflammation ,Animal ,Tumor Necrosis Factor-alpha ,BLOOD-BRAIN-BARRIER ,Cell Biology ,MyD88 ,MICROGLIAL ACTIVATION ,Receptors, Formyl Peptide ,Toll-Like Receptor 4 ,MODEL ,030104 developmental biology ,RESOLUTION ,TLR4 ,biology.protein ,TNF alpha ,030217 neurology & neurosurgery - Abstract
Background: Annexin A1 (ANXA1) and Translocator Protein-18KDa (TSPO) down-regulate neuroinflammation. We investigated the role of recombinant ANXA1 (rANXA) on TSPO functions on Toll Like Receptor (TLR) activated microglia. Methods: BV-2 cells (murine microglia), were stimulated by E. coli Lipopolysaccharide (LPS) and treated with rANXA1 in order to measure TSPO expression and inflammatory parameters. Anti-sense ANXA1 and TLR4 and TSPO shRNA, as well as pharmacological treatments, were employed to assess the mechanisms involved. Results: LPS-stimulated BV-2 cells caused overexpression of TSPO, which was inhibited by: pharmacological blockade of TLR4 or TLR4 mRNA silencing; inhibition of myeloid differentiation primary response gene 88 (MyD88) dimerization; or blocking of nuclear factor kappa B (NF-kappa B) activation. rANXA1 treatment impaired LPS-induced TSPO upregulation by down-modulating MyD88 and NF-kappa B signaling; the effect was abolished by WRW4, an antagonist of formyl peptide receptor 2 (FPR2). rANXA1 treatment also downregulated interleukin 1 beta (IL-1 beta) and tumor necrosis factor-alpha (TNF alpha) secretion in LPS-stimulated BV-2 cells. TSPO knockdown in BV-2 cells augmented LPS-induced TNFa secretion and abolished the inhibitory effect of rANXA1 on TNF alpha secretion evoked by LPS. Conclusions: exogenous ANXA1 down-modulates LPS-induced TSPO via MyD-88/NF-kappa B pathways, and constitutive TSPO is pivotal for the control of ANXA1 on TNF alpha secretion. TSPO actions may be involved with the mechanisms of ANXA1 on inflammatory brain diseases.
- Published
- 2018
25. SOX10 requirement for melanoma tumor growth is due, in part, to immune-mediated effects
- Author
-
Sheera R. Rosenbaum, Manoela Tiago, Signe Caksa, Claudia Capparelli, Timothy J. Purwin, Gaurav Kumar, McKenna Glasheen, Danielle Pomante, Daniel Kotas, Inna Chervoneva, and Andrew E. Aplin
- Subjects
Male ,Skin Neoplasms ,Mice, SCID ,CD8-Positive T-Lymphocytes ,Article ,General Biochemistry, Genetics and Molecular Biology ,Lymphocytes, Tumor-Infiltrating ,Antigens, CD ,Mice, Inbred NOD ,Cell Line, Tumor ,Databases, Genetic ,Animals ,Humans ,Melanoma ,Cell Proliferation ,SOXE Transcription Factors ,biochemical phenomena, metabolism, and nutrition ,Carcinoembryonic Antigen ,Tumor Burden ,Gene Expression Regulation, Neoplastic ,Mice, Inbred C57BL ,embryonic structures ,bacteria ,Cell Adhesion Molecules ,Receptors, Tumor Necrosis Factor, Member 14 ,Signal Transduction - Abstract
SUMMARY Developmental factors may regulate the expression of immune modulatory proteins in cancer, linking embryonic development and cancer cell immune evasion. This is particularly relevant in melanoma because immune checkpoint inhibitors are commonly used in the clinic. SRY-box transcription factor 10 (SOX10) mediates neural crest development and is required for melanoma cell growth. In this study, we investigate immune-related targets of SOX10 and observe positive regulation of herpesvirus entry mediator (HVEM) and carcinoembryonic-antigen cell-adhesion molecule 1 (CEACAM1). Sox10 knockout reduces tumor growth in vivo, and this effect is exacerbated in immune-competent models. Modulation of CEACAM1 expression but not HVEM elicits modest effects on tumor growth. Importantly, Sox10 knockout effects on tumor growth are dependent, in part, on CD8+ T cells. Extending this analysis to samples from patients with cutaneous melanoma, we observe a negative correlation with SOX10 and immune-related pathways. These data demonstrate a role for SOX10 in regulating immune checkpoint protein expression and anti-tumor immunity in melanoma., In brief SOX10 is a lineage-specific transcription factor that facilitates neural crest cell development and contributes to melanoma cell growth. Rosenbaum et al. investigate potential immune-related roles for SOX10 in melanoma. They observe that Sox10 knockout reduces expression of the immune checkpoint proteins HVEM and CEACAM1 and mediates effects on tumor growth in immune-competent models., Graphical Abstract
- Published
- 2021
26. Correction: Synthetic Lethal Screens Reveal Cotargeting FAK and MEK as a Multimodal Precision Therapy for GNAQ-Driven Uveal Melanoma
- Author
-
Justine S. Paradis, Monica Acosta, Robert Saddawi-Konefka, Ayush Kishore, Simone Lubrano, Frederico Gomes, Nadia Arang, Manoela Tiago, Silvia Coma, Xingyu Wu, Kyle Ford, Chi-Ping Day, Glenn Merlino, Prashant Mali, Jonathan A. Pachter, Takami Sato, Andrew E. Aplin, and J. Silvio Gutkind
- Subjects
Cancer Research ,Oncology - Published
- 2021
27. Abstract 40: Targeting SOX10-deficient cells to reduce resistance to targeted therapy in melanoma
- Author
-
Weijia Cai, Adam E. Snook, McKenna Glasheen, Inna Chervoneva, Sheera Rosenbaum, Ayako Shimada, Mai Q. Nguyen, Andrew E. Aplin, Danielle Pomante, Claudia Capparelli, Xiaowei Xu, Manoela Tiago, Kim HooKim, Timothy J. Purwin, Michael A. Davies, Meenhard Herlyn, Edna Cukierman, Gaurav Kumar, Nicole A. Wilski, Richard Zheng, and Paolo Fortina
- Subjects
Cancer Research ,Oncology ,business.industry ,medicine.medical_treatment ,Melanoma ,embryonic structures ,SOX10 ,medicine ,Cancer research ,business ,medicine.disease ,Targeted therapy - Abstract
Intratumoral heterogeneity and cellular plasticity enable tumors to alter phenotypes and adapt to foreign microenvironments and resist targeted inhibitors. While the ability to switch between phenotypic states has been broadly characterized, the key mechanisms that underlie tumor plasticity remain poorly understood. We studied the neural crest lineage transcription factor, SOX10, in the context of cutaneous melanoma and resistance to targeted therapies. SOX10 is heterogeneously expressed in melanoma samples. Using bio-informatics as well as in vivo and 3D in vitro melanoma models, SOX10 loss was sufficient to induce an invasive but slow proliferating phenotype in vitro and in vivo that was associated with expression of a mesenchymal gene set. Interestingly, while SOX10 knockout initially induced a targeted inhibitor tolerant state, longer exposure of co-mixed populations of SOX10 proficient and SOX10 deficient to targeted therapy drives the clonal selection of SOX10 knockout cells. Furthermore, cell lines generated from xenograft tumors that have acquired resistance to either vemurafenib, paradox-breaking BRAFi or the combination of BRAFi + MEKi showed dramatically reduced SOX10 expression compared to their parental counterparts. Altogether these data suggest that acquired resistant clones may arise from drug tolerant persister cells. As a strategy to selectively target this invasive, drug-tolerant SOX10-deficient sub-population, we screened a drug compound library and identified a class of cIAP1/2 inhibitors to be synthetically lethal for SOX10-deficient cells. Our preliminary data suggest that birinapant can delay or prevent resistance to BRAFi/MEKi in vivo. Together, these data suggest that SOX10 mediates phenotypic switching in cutaneous melanoma and enables tumor adaptation to altered microenvironments and drug treatments which could be targeted using cIAP1/2 inhibitors. Citation Format: Claudia Capparelli, Timothy J. Purwin, Manoela Tiago, Nicole Wilski, Danielle Pomante, McKenna Glasheen, Sheera Rosenbaum, Mai Q. Nguyen, Weijia Cai, Richard Zheng, Gaurav Kumar, Inna Chervoneva, Ayako Shimada, Adam E. Snook, Paolo Fortina, Xiaowei Xu, Kim Hookim, Edna Cukierman, Michael A. Davies, Meenhard Herlyn, Andrew E. Aplin. Targeting SOX10-deficient cells to reduce resistance to targeted therapy in melanoma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr 40.
- Published
- 2021
28. The next‐generation BET inhibitor, PLX51107, delays melanoma growth in a CD8‐mediated manner
- Author
-
Dan A. Erkes, Andrew E. Aplin, Timothy J. Purwin, Inna Chervoneva, Adam C. Berger, Jessie Villanueva, Manoela Tiago, Claudia Capparelli, Edward J. Hartsough, and Conroy O. Field
- Subjects
Male ,0301 basic medicine ,Pyridines ,Antineoplastic Agents ,Apoptosis ,Dermatology ,CD8-Positive T-Lymphocytes ,Article ,General Biochemistry, Genetics and Molecular Biology ,Fas ligand ,BET inhibitor ,Mice ,03 medical and health sciences ,0302 clinical medicine ,Immune system ,Tumor Cells, Cultured ,medicine ,Animals ,Humans ,Pyrroles ,Epigenetics ,Melanoma ,Oxazoles ,Cell Proliferation ,Tumor microenvironment ,Chemistry ,Proteins ,medicine.disease ,Xenograft Model Antitumor Assays ,Bromodomain ,Mice, Inbred C57BL ,030104 developmental biology ,Oncology ,030220 oncology & carcinogenesis ,Cancer research ,CD8 - Abstract
Epigenetic agents such as bromodomain and extra-terminal region inhibitors (BETi) slow tumor growth via tumor intrinsic alterations; however, their effects on antitumor immunity remain unclear. A recent advance is the development of next-generation BETi that are potent and display a favorable half-life. Here, we tested the BETi, PLX51107, for immune-based effects on tumor growth in BRAF V600E melanoma syngeneic models. PLX51107 delayed melanoma tumor growth and increased activated, proliferating, and functional CD8+ T cells in tumors leading to CD8+ T-cell-mediated tumor growth delay. PLX51107 decreased Cox2 expression, increased dendritic cells, and lowered PD-L1, FasL, and IDO-1 expression in the tumor microenvironment. Importantly, PLX51107 delayed the growth of tumors that progressed on anti-PD-1 therapy; a response associated with decreased Cox2 levels, decreased PD-L1 expression on non-immune cells, and increased intratumoral CD8+ T cells. Thus, next-generation BETi represent a potential first-line and secondary treatment strategy for metastatic melanoma by eliciting effects, at least in part, on antitumor CD8+ T cells.
- Published
- 2019
29. Targeting BRD/BET proteins inhibits adaptive kinome upregulation and enhances the effects of BRAF/MEK inhibitors in melanoma
- Author
-
Shea A. Heilman, Michael A. Davies, Claudia Capparelli, Adam C. Berger, Andrew E. Aplin, Manoela Tiago, Timothy J. Purwin, and Dan A. Erkes
- Subjects
Proto-Oncogene Proteins B-raf ,Cancer Research ,medicine.medical_treatment ,Tumour heterogeneity ,Mice, Nude ,Transfection ,Receptor tyrosine kinase ,Article ,Targeted therapy ,BET inhibitor ,03 medical and health sciences ,chemistry.chemical_compound ,Mice ,0302 clinical medicine ,Downregulation and upregulation ,Medicine ,Animals ,Humans ,ERBB3 ,Kinome ,Melanoma ,Protein Kinase Inhibitors ,030304 developmental biology ,0303 health sciences ,biology ,Molecular medicine ,business.industry ,medicine.disease ,Up-Regulation ,Oncology ,chemistry ,030220 oncology & carcinogenesis ,Cancer research ,biology.protein ,Growth inhibition ,business - Abstract
Background BRAF-mutant melanoma patients respond to BRAF inhibitors and MEK inhibitors (BRAFi/MEKi), but drug-tolerant cells persist, which may seed disease progression. Adaptive activation of receptor tyrosine kinases (RTKs) has been associated with melanoma cell drug tolerance following targeted therapy. While co-targeting individual RTKs can enhance the efficacy of BRAFi/MEKi effects, it remains unclear how to broadly target multiple RTKs to achieve more durable tumour growth inhibition. Methods The blockage of adaptive RTK responses by the new BET inhibitor (BETi), PLX51107, was measured by RPPA and Western blot. Melanoma growth was evaluated in vitro by colony assay and EdU staining, as well as in skin reconstructs, xenografts and PDX models following BRAFi, MEKi and/or PLX51107 treatment. Results Treatment with PLX51107 limited BRAFi/MEKi upregulation of ErbB3 and PDGFR-β expression levels. Similar effects were observed following BRD2/4 depletion. In stage III melanoma patients, expression of BRD2/4 was strongly correlated with ErbB3. PLX51107 enhanced the effects of BRAFi/MEKi on inhibiting melanoma growth in vitro, in human skin reconstructs and in xenografts in vivo. Continuous triple drug combination treatment resulted in significant weight loss in mice, but intermittent BETi combined with continuous BRAFi/MEKi treatment was tolerable and improved durable tumour inhibition outcomes. Conclusions Together, our data suggest that intermittent inhibition of BET proteins may improve the duration of responses following BRAFi/MEKi treatment in BRAF-mutant melanoma.
- Published
- 2019
30. BET inhibition modifies melanoma infiltrating T cells and enhances response to PD-L1 blockade
- Author
-
Neda Nikbakht, Andrew E. Aplin, Dan A. Erkes, Manoela Tiago, and Inna Chervoneva
- Subjects
Skin Neoplasms ,Regulatory T cell ,Pyridines ,Programmed Cell Death 1 Receptor ,Nerve Tissue Proteins ,Receptors, Cell Surface ,Dermatology ,Cell Growth Processes ,CD8-Positive T-Lymphocytes ,Biochemistry ,T-Lymphocytes, Regulatory ,Drug synergism ,Article ,Mice ,Text mining ,Antineoplastic Agents, Immunological ,Lymphocytes, Tumor-Infiltrating ,PD-L1 ,Cell Line, Tumor ,medicine ,Animals ,Humans ,Pyrroles ,Receptor ,Molecular Biology ,Melanoma ,Oxazoles ,biology ,business.industry ,Chemistry ,Drug Synergism ,Forkhead Transcription Factors ,Cell Biology ,medicine.disease ,Blockade ,Tumor Burden ,Disease Models, Animal ,medicine.anatomical_structure ,Cell culture ,biology.protein ,Cancer research ,Immunotherapy ,business - Published
- 2019
31. CADM1 is a TWIST1-regulated suppressor of invasion and survival
- Author
-
Curtis H. Kugel, Timothy J. Purwin, Manoela Tiago, Sheera Rosenbaum, Shea A. Heilman, Andrew E. Aplin, Edward J. Hartsough, Inna Chervoneva, Michele B. Weiss, Dan A. Erkes, and Kim HooKim
- Subjects
0301 basic medicine ,Cancer Research ,Epithelial-Mesenchymal Transition ,Skin Neoplasms ,Immunology ,Biology ,Transfection ,Article ,Transcriptome ,03 medical and health sciences ,Cellular and Molecular Neuroscience ,0302 clinical medicine ,Cell Line, Tumor ,medicine ,Biomarkers, Tumor ,Humans ,Anoikis ,Neoplasm Invasiveness ,Epithelial–mesenchymal transition ,lcsh:QH573-671 ,Promoter Regions, Genetic ,Melanoma ,Regulation of gene expression ,Membrane Potential, Mitochondrial ,lcsh:Cytology ,Twist-Related Protein 1 ,Cell Adhesion Molecule-1 ,Nuclear Proteins ,Cell Biology ,medicine.disease ,Prognosis ,Cell aggregation ,Progression-Free Survival ,Gene expression profiling ,Gene Expression Regulation, Neoplastic ,030104 developmental biology ,Tissue Array Analysis ,030220 oncology & carcinogenesis ,Cancer research ,Chromatin immunoprecipitation - Abstract
Metastatic cancer remains a clinical challenge; however, patients diagnosed prior to metastatic dissemination have a good prognosis. The transcription factor, TWIST1 has been implicated in enhancing the migration and invasion steps within the metastatic cascade, but the range of TWIST1-regulated targets is poorly described. In this study, we performed expression profiling to identify the TWIST1-regulated transcriptome of melanoma cells. Gene ontology pathway analysis revealed that TWIST1 and epithelial to mesenchymal transition (EMT) were inversely correlated with levels of cell adhesion molecule 1 (CADM1). Chromatin immunoprecipitation (ChIP) studies and promoter assays demonstrated that TWIST1 physically interacts with the CADM1 promoter, suggesting TWIST1 directly represses CADM1 levels. Increased expression of CADM1 resulted in significant inhibition of motility and invasiveness of melanoma cells. In addition, elevated CADM1 elicited caspase-independent cell death in non-adherent conditions. Expression array analysis suggests that CADM1 directed non-adherent cell death is associated with loss of mitochondrial membrane potential and subsequent failure of oxidative phosphorylation pathways. Importantly, tissue microarray analysis and clinical data from TCGA indicate that CADM1 expression is inversely associated with melanoma progression and positively correlated with better overall survival in patients. Together, these data suggest that CADM1 exerts tumor suppressive functions in melanoma by reducing invasive potential and may be considered a biomarker for favorable prognosis.
- Published
- 2018
32. Indoleamine 2,3-dioxygenase in melanoma progression and BRAF inhibitor resistance
- Author
-
Vinicius de Lima Vazquez, Fernanda Faião-Flores, Paola da Costa Souza, Erica Aparecida de Oliveira, Ana Campa, Silene Migliorini, Marcia Edilaine Lopes Consolaro, Aloísio Felipe-Silva, Luis Roberto Masao Watanabe, Silvana Sandri, Silvya Stuchi Maria-Engler, and Manoela Tiago
- Subjects
Proto-Oncogene Proteins B-raf ,0301 basic medicine ,Skin Neoplasms ,In silico ,medicine.medical_treatment ,Antineoplastic Agents ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Immune system ,Cell Line, Tumor ,Databases, Genetic ,medicine ,Humans ,Indoleamine-Pyrrole 2,3,-Dioxygenase ,Molecular Targeted Therapy ,Indoleamine 2,3-dioxygenase ,Melanoma ,Protein Kinase Inhibitors ,Pharmacology ,Messenger RNA ,business.industry ,Therapeutic effect ,Tryptophan ,medicine.disease ,030104 developmental biology ,Vemurafenib ,chemistry ,Drug Resistance, Neoplasm ,030220 oncology & carcinogenesis ,Cancer research ,business ,Adjuvant ,Kynurenine - Abstract
Indoleamine 2,3-dioxygenase (IDO) is associated with the progression of many types of tumors, including melanoma. However, there is limited information about IDO modulation on tumor cell itself and the effect of BRAF inhibitor (BRAFi) treatment and resistance. Herein, IDO expression was analyzed in different stages of melanoma development and progression linked to BRAFi resistance. IDO expression was increased in primary and metastatic melanomas from patients' biopsies, especially in the immune cells infiltrate. Using a bioinformatics approach, we also identified an increase in the IDO mRNA in the vertical growth and metastatic phases of melanoma. Using in silico analyses, we found that IDO mRNA was increased in BRAFi resistance. In an in vitro model, IDO expression and activity induced by interferon-gamma (IFNγ) in sensitive melanoma cells was decreased by BRAFi treatment. However, cells that became resistant to BRAFi presented random IDO expression levels. Also, we identified that treatment with the IDO inhibitor, 1-methyltryptophan (1-MT), was able to reduce clonogenicity for parental and BRAFi-resistant cells. In conclusion, our results support the hypothesis that the decreased IDO expression in tumor cells is one of the many additional outcomes contributing to the therapeutic effects of BRAFi. Still, the IDO production changeability by the BRAFi-resistant cells reiterates the complexity of the response arising from resistance, making it not possible, at this stage, to associate IDO expression in tumor cells with resistance. On the other hand, the maintenance of 1-MT off-target effect endorses its use as an adjuvant treatment of melanoma that has become BRAFi-resistant.
- Published
- 2020
33. Abstract 2986: NR2F1 underlies persistence of residual disease in melanoma
- Author
-
Connor Hollingworth, Manoela Tiago, Andrew E. Aplin, Weijia Cai, Melisa Lopez-Anton, Jessica L.F. Teh, Timothy J. Purwin, and Julio A. Aguirre-Ghiso
- Subjects
Persistence (psychology) ,Cancer Research ,Oncology ,Melanoma ,Immunology ,medicine ,Disease ,Biology ,medicine.disease ,Residual - Abstract
Despite the clinical success of targeted therapy and checkpoint inhibitors in melanoma, therapeutic responses are transient, followed by relapse that may be driven by a small subpopulation of residual or drug-tolerant cells. Understanding residual disease and metastasis mechanisms can provide clues both for developing improved versions of a drug and for guiding the selection of appropriate drug combinations for melanoma therapy. Here, we found that the well-known marker of tumor dormancy, Nuclear Receptor Subfamily 2 Group F Member 1 (NR2F1), was overexpressed in minimal disease residual cells following CDK4/6 and MEK inhibitors (CDK4/6i+MEKi) treatment in vivo. Furthermore, melanoma cells overexpressing NR2F1 were less sensitive to (CDK4/6i+MEKi) or BRAF and MEK inhibitors (BRAFi+MEKi) treatment in vitro and in vivo models, inhibiting apoptosis. Surprisingly, we did not find any evidence of decreased cell growth in our model. Using a three-dimensional tumor spheroid assay in vitro, we found the NR2F1 expression enhanced melanoma invasion following CDK4/6i+MEKi or BRAFi+MEKi treatments. The use of published RNA Seq data sets that were gathered from the GEO database and Single Cell Seq data sets from PDX melanoma samples showed that high expression of NR2F1 is enriched in the undifferentiated cell state and invasive cells, respectively. Furthermore, BRAF mutant patient sample with an acquired mutation in NRAS Q61R following BRAFi+MEKi+CDKi presented a high expression of NR2F1. Altogether, these findings suggest that NR2F1 may play a role in residual disease persistence besides known features of tumor dormancy, especially important in determining responses to dramatic changes in the environment, such as changes induced by anti-cancer therapy. Citation Format: Manoela Tiago, Jessica L. Teh, Timothy J. Purwin, Weijia Cai, Connor Hollingworth, Melisa Lopez-Anton, Julio A. Aguirre-Ghiso, Andrew E. Aplin. NR2F1 underlies persistence of residual disease in melanoma [abstract]. In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-28 and Jun 22-24. Philadelphia (PA): AACR; Cancer Res 2020;80(16 Suppl):Abstract nr 2986.
- Published
- 2020
34. Abstract A33: The next-generation BET inhibitor, PLX51107, delays melanoma growth, altering the tumor immune microenvironment via Cox2 inhibition
- Author
-
Edward J. Hartsough, Sheera Rosenbaum, Conroy O. Field, Adam C. Berger, Jessie Villanueva, Manoela Tiago, Shea A. Heilman, Claudia Capparelli, Andrew E. Aplin, Inna Chervoneva, Timothy J. Purwin, and Dan A. Erkes
- Subjects
Cancer Research ,biology ,Melanoma ,medicine.medical_treatment ,Immunology ,Cancer ,Immunotherapy ,Major histocompatibility complex ,medicine.disease ,Fas ligand ,BET inhibitor ,Immune system ,biology.protein ,medicine ,Cancer research ,CD8 - Abstract
Epigenetic agents such as bromodomain and extra terminal domain inhibitors (BETi) slow tumor growth via tumor intrinsic alterations; however, their effects on antitumor immunity remain unclear. A recent advance is the development of next-generation BETi that are potent and display a favorable half-life. Here, we tested the next-generation BETi, PLX51107, for immune-based effects on tumor growth in BRAF V600E melanoma syngeneic models. PLX51107 delayed melanoma tumor growth to differing degrees and altered the immunogenicity by lowering PD-L1 and FasL and increasing MHC-I in highly responsive melanomas. Moreover, PLX51107 treatment increased activated, proliferating and functional CD8+ T cells in tumors, leading to CD8+ T-mediated tumor growth delay. PLX51107 led to increased CD8-promoting, antitumor dendritic cells by acting as a Cox2 inhibitor. The accumulation of CSF-1R+ tumor-associated macrophages in poorly responsive melanoma limited PLX51107 efficacy. Importantly, PLX51107 delayed the growth of tumors that progressed on anti-PD-1 therapy, a response associated with decreased Cox2 levels, decreased PD-L1 expression and increased MHC-I expression on nonhematopoietic cells and increased intratumoral CD8+ T cells. Thus, next-generation BETi represent a potential first-line and secondary treatment strategy for metastatic melanoma by eliciting effects, at least in part, on antitumor immunity. Citation Format: Dan A. Erkes, Conroy O. Field, Claudia Capparelli, Manoela Tiago, Timothy J. Purwin, Shea A. Heilman, Inna Chervoneva, Adam C. Berger, Sheera R. Rosenbaum, Edward J. Hartsough, Jessie Villanueva, Andrew E. Aplin. The next-generation BET inhibitor, PLX51107, delays melanoma growth, altering the tumor immune microenvironment via Cox2 inhibition [abstract]. In: Proceedings of the AACR Special Conference on Tumor Immunology and Immunotherapy; 2018 Nov 27-30; Miami Beach, FL. Philadelphia (PA): AACR; Cancer Immunol Res 2020;8(4 Suppl):Abstract nr A33.
- Published
- 2020
35. Three-Dimensional Systems in Polybutylcyanoacrylate Nanoparticles Safety Evaluation
- Author
-
Glaucia Cristina Mello Santos, Silvya Stuchi Maria-Engler, Manoela Tiago, and Terezinha de Jesus Andreoli Pinto
- Subjects
Cell physiology ,Programmed cell death ,Cell type ,Materials science ,Polymers and Plastics ,medicine.diagnostic_test ,General Chemical Engineering ,Nanotechnology ,Analytical Chemistry ,Flow cytometry ,chemistry.chemical_compound ,chemistry ,Cell culture ,Monolayer ,medicine ,Biophysics ,Trypan blue ,Cytotoxicity - Abstract
It is generally accepted that three-dimensional (3D) cell culture systems better represent cell physiology and morphology than two-dimensional (monolayer) cell cultures. The aim of this work was to develop a 3D model that could efficiently evaluate polymeric materials biocompatibility using polybutylcyanoacrylate nanoparticles (PBCA-NP). Normal human fibroblasts and melanoma cells were cultured both in monolayer and on type I collagen matrix. Trypan blue and MTT assays were used to evaluate PBCA-NP cytotoxicity, which was shown to be dose- and time-dependent to all cell types. These results were confirmed by cell death analysis with flow cytometry. There is evidence that treatment with PBCA-NP in concentrations close to the IC50 inhibit autophagy in fibroblasts and melanoma cells when cultured in monolayer, but this response could not be observed in the 3D system. These findings strongly suggest that PBCA-NP can modify cell response depending on the concentration used and the conditions of cell culture.
- Published
- 2015
36. Molecular effects of 1-naphthyl-methylcarbamate and solar radiation exposures on human melanocytes
- Author
-
Silvya Stuchi Maria-Engler, Silvia Berlanga de Moraes Barros, Richard S. Paules, Manoela Tiago, Richard D. Fannin, Bianca Ferrucio, Liwen Liu, and Kevin Gerrish
- Subjects
Male ,0301 basic medicine ,Cell Survival ,Ultraviolet Rays ,DNA damage ,Apoptosis ,Pyrimidine dimer ,Biology ,Carbaryl ,Toxicology ,medicine.disease_cause ,Article ,RADIAÇÃO ULTRAVIOLETA ,03 medical and health sciences ,chemistry.chemical_compound ,Downregulation and upregulation ,medicine ,Humans ,Child ,Cells, Cultured ,Genetics ,integumentary system ,Cell Cycle ,General Medicine ,Cell cycle ,Endoplasmic Reticulum Stress ,Microphthalmia-associated transcription factor ,Molecular biology ,Oxidative Stress ,030104 developmental biology ,chemistry ,Child, Preschool ,Sunlight ,Melanocytes ,Carcinogenesis ,Cell Division ,Oxidative stress ,DNA Damage - Abstract
Carbaryl (1-naphthyl-methylcarbamate), a broad-spectrum insecticide, has recently been associated with the development of cutaneous melanoma in an epidemiological cohort study with U.S. farm workers also exposed to ultraviolet radiation, the main etiologic factor for skin carcinogenesis. We hypothesized that carbaryl exposure may increase deleterious effects of UV solar radiation on skin melanocytes. This study aimed to characterize human melanocytes after individual or combined exposure to carbaryl (100 μM) and solar radiation (375 mJ/cm2). In a microarray analysis, carbaryl, but not solar radiation, induced an oxidative stress response, evidenced by the upregulation of antioxidant genes, such as Hemeoxygenase-1 (HMOX1), and downregulation of Microphtalmia-associated Transcription Factor (MITF), the main regulator of melanocytic activity; results were confirmed by qRT-PCR. Carbaryl and solar radiation induced a gene response suggestive of DNA damage and cell cycle alteration. The expression of CDKN1A, BRCA1/2 and MDM2 genes was notably more intense in the combined treatment group, in a synergistic manner. Flow cytometry assays demonstrated S-phase cell cycle arrest, reduced apoptosis levels and faster induction of cyclobutane pyrimidine dimers (CPD) lesions in carbaryl treated groups. Our data suggests that carbaryl is genotoxic to human melanocytes, especially when associated with solar radiation.
- Published
- 2017
37. Vemurafenib resistance increases melanoma invasiveness and modulates the tumor microenvironment by MMP-2 upregulation
- Author
-
Adriane Feijó Evangelista, Manoela Tiago, Paula Comune Pennacchi, Vinicius de Lima Vazquez, Renato Ramos Massaro, Silvana Sandri, Fernanda Faião-Flores, Gustavo Noriz Berardinelli, Silvya Stuchi Maria-Engler, Débora Kristina Alves-Fernandes, Rui Manuel Reis, [et. al.], and Universidade do Minho
- Subjects
Proto-Oncogene Proteins B-raf ,Indoles ,Matrix metalloproteinase inhibitor ,Antineoplastic Agents ,MELANOMA ,Biology ,GPI-Linked Proteins ,BRAF-resistant melanoma ,Downregulation and upregulation ,Cell Line, Tumor ,Matrix Metalloproteinase 14 ,Tumor Microenvironment ,medicine ,Humans ,Neoplasm Invasiveness ,Interleukin 8 ,Kinase activity ,Vemurafenib ,Melanoma ,Protein Kinase Inhibitors ,Metalloproteinase ,Secretome ,Pharmacology ,MMP-2, BRAF-resistant melanoma ,Sulfonamides ,Tissue Inhibitor of Metalloproteinase-2 ,Tumor microenvironment ,Science & Technology ,MMP-2 ,Interleukin-8 ,Tumor microenvironment, secretome, 3D skin reconstruction ,medicine.disease ,Up-Regulation ,Matrix Metalloproteinase 9 ,Drug Resistance, Neoplasm ,Cancer research ,Matrix Metalloproteinase 2 ,3D skin reconstruction ,V600E ,medicine.drug - Abstract
The BRAF(V600E) mutation confers constitutive kinase activity and accounts for >90% of BRAF mutations in melanoma. This genetic alteration is a current therapeutic target; however, the antitumorigenic effects of the BRAF(V600E) inhibitor vemurafenib are short-lived and the majority of patients present tumor relapse in a short period after treatment. Characterization of vemurafenib resistance has been essential to the efficacy of next generation therapeutic strategies. Herein, we found that acute BRAF inhibition induced a decrease in active MMP-2, MT1-MMP and MMP-9, but did not modulate the metalloproteinase inhibitors TIMP-2 or RECK in naive melanoma cells. In vemurafenib-resistant melanoma cells, we observed a lower growth rate and an increase in EGFR phosphorylation followed by the recovery of active MMP-2 expression, a mediator of cancer metastasis. Furthermore, we found a different profile of MMP inhibitor expression, characterized by TIMP-2 downregulation and RECK upregulation. In a 3D spheroid model, the invasion index of vemurafenib-resistant melanoma cells was more evident than in its non-resistant counterpart. We confirmed this pattern in a matrigel invasion assay and demonstrated that use of a matrix metalloproteinase inhibitor reduced the invasion of vemurafenib resistant melanoma cells but not drug naive cells. Moreover, we did not observe a delimited group of cells invading the dermis in vemurafenib-resistant melanoma cells present in a reconstructed skin model. The same MMP-2 and RECK upregulation profile was found in this 3D skin model containing vemurafenib-resistant melanoma cells. Acute vemurafenib treatment induces the disorganization of collagen fibers and consequently, extracellular matrix remodeling, with this pattern observed even after the acquisition of resistance. Altogether, our data suggest that resistance to vemurafenib induces significant changes in the tumor microenvironment mainly by MMP-2 upregulation, with a corresponding increase in cell invasiveness., This study was supported by Fundacao de Amparo a Pesquisa do Estado de Sao Paulo [grant no 2014/24400-0; 2013/05172-4 (Postdoctoral fellowship)]; and Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior/PRODOC [grant no 3193-32/2010]. S.S., F.F.F. S.S.M.E. designed research, analyzed data and, wrote the paper; S.S. and F.F.F. performed all experiments; M.T., P.C.P, R.R.M, D.K.A.F., G.N.B, A.F.E. performed some experiments; V.L.V and R.M.R analyzed data and, wrote the paper, info:eu-repo/semantics/publishedVersion
- Published
- 2016
38. Proteasome inhibition and ROS generation by 4-nerolidylcatechol induces melanoma cell death
- Author
-
Renata Chaves Albuquerque, Ana Paula de Melo Loureiro, Manoela Tiago, Camila Eduardo Marinho, Maria S. Soengas, Diogo Pineda Rivelli, Tiago Franco de Oliveira, Silvya Stuchi Maria-Engler, Silvia Berlanga de Moraes Barros, Sabrina Sayori Okada, Carla Abdo Brohem, Rebeca Leite de Almeida, Renato Ramos Massaro, and Miriam Galvonas Jasiulionis
- Subjects
Chemotherapy ,Programmed cell death ,Antioxidant ,medicine.medical_treatment ,Melanoma ,Human skin ,Dermatology ,Biology ,medicine.disease ,General Biochemistry, Genetics and Molecular Biology ,Cell biology ,Oncology ,Apoptosis ,Tumor progression ,medicine ,Cytotoxic T cell - Abstract
Summary Induction of apoptotic cell death in response to chemotherapy and other external stimuli has proved extremely difficult in melanoma, leading to tumor progression, metastasis formation and resistance to therapy. A promising approach for cancer chemotherapy is the inhibition of proteasomal activity, as the half-life of the majority of cellular proteins is under proteasomal control and inhibitors have been shown to induce cell death programs in a wide variety of tumor cell types. 4-Nerolidylcatechol (4-NC) is a potent antioxidant whose cytotoxic potential has already been demonstrated in melanoma tumor cell lines. Furthermore, 4-NC was able to induce the accumulation of ubiquitinated proteins, including classic targets of this process such as Mcl-1. As shown for other proteasomal inhibitors in melanoma, the cytotoxic action of 4-NC is time-dependent upon the pro-apoptotic protein Noxa, which is able to bind and neutralize Mcl-1. We demonstrate the role of 4-NC as a potent inducer of ROS and p53. The use of an artificial skin model containing melanoma also provided evidence that 4-NC prevented melanoma proliferation in a 3D model that more closely resembles normal human skin.
- Published
- 2012
39. Mechanisms of epigenetic regulation and tumor clonal heterogeneity in human metastatic melanoma involving RECK gene
- Author
-
Manoela Tiago dos Santos, Silvya Stuchi Maria-Engler, Daniela Sanchez Bassères, Erico Tosoni Costa, and Ana Cristina Victorino Krepischi
- Abstract
Os pacientes com melanomas, em geral, apresentam extrema quimiorresistência e prognóstico ruim, com taxa de sobrevida de aproximadamente seis meses; portanto, novas estratégias terapêuticas são necessárias. As células deste tipo de tumor acumulam alterações na expressão gênica que contribuem para a proliferação descontrolada, evasão de senescência e inibição de morte celular em múltiplas rotas intracelulares. No Capítulo 1, foi explorado o controle epigenético do supressor tumoral RECK. Esse gene é largamente expresso em tecidos normais, com correlação de sua expressão com melhor prognóstico. Em tumores, RECK é inibido, incluindo em melanoma. Neste estudo, sua inibição por hipermetilação do promotor e remodelamento da cromatina por HDACs não foi o único fator inibitório nas linhagens de melanoma analisadas. Mesmo após a utilização a remoção de marcas epigenéticas associadas ao silenciamento gênico, a expressão proteica não pôde ser recuperada nas linhagens utilizadas neste trabalho. No Capítulo 2, isolou-se subpopulações clonais ao acaso a fim de modelar a heterogeneidade tumoral intrínseca. Neste modelo experimental, caracterizamos a presença de dois perfis tumorais subclonais: uma mais proliferativa, invasiva e sensível a vemurafenibe; e outra menos proliferativa, mais resistente e com maior expressão de RECK e fatores ligados a EMT. Nossos resultados, em conjunto, mostraram que as linhagens celulares parentais utilizadas apresentam diferenças entre si quanto à viabilidade celular, indução de apoptose e fosforilação de ERK após o tratamento com vemurafenibe. Segundo o nosso modelo, a resistência intrínseca ao vemurafenibe está presente e reflete a heterogeneidade do tumor inicial. Com estes resultados, pretendemos contribuir para o conhecimento sobre a composição clonal presente na heterogeneidade tumoral, além de contribuir para a função de RECK na biologia do melanoma. Patients with melanoma often present extreme chemoresistance and poor prognosis, with survival rates of approximately six months; therefore, new therapeutic strategies are necessary. Melanoma cells accumulate genotypic changes that contribute to uncontrolled proliferation, evasion of senescence and cell death inhibition in multiple cellular pathways. In Chapter 1, we have explored the epigenetic control of the tumor suppressor RECK. This gene is widely expressed in normal tissues, with correlation of its expression with better prognosis. In tumors, RECK is inhibited, including melanoma. Here, RECK inhibition by promoter hypermethylation and chromatin remodeling by HDACs was not the only inhibiting factor in the melanoma cell lines analyzed. Even after removing the epigenetic marks associated to gene expression silencing, the protein expression could not be recovered in the cell lines used in this study. In Chapter 2, it has been isolated several tumor clonal subpopulations in order to modulate the intrinsic tumor heterogeneity. In this experimental model, we have characterized the presence of two tumor subclonal profiles: a more proliferative, invasive and sensitive to Vemurafenib; and other less proliferative, less sensitive to Vemurafenib and presenting more expression of RECK and factors associated to EMT. Our results together have showed the parental cell lines used here differed from each other in terms of cell viability, induction of apoptosis, and ERK phosphorylation after treatment with Vemurafenib. According to our model, the intrinsic resistance to Vemurafenib is present and reflects the heterogeneity of the initial tumor. With these results, we intend to contribute to the knowledge of the tumor clonal subpopulations composition in tumor heterogeneity, and contributes to the RECK function in melanoma biology.
- Published
- 2015
40. Prospecção de novos fármacos para melanoma em equivalente dérmico
- Author
-
Manoela Tiago dos Santos, Silvya Stuchi Maria-Engler, Erico Tosoni Costa, and Miriam Galvonas Jasiulionis
- Abstract
Os modelos de reconstrução do microambiente são úteis para investigar as propriedades biológicas dos melanócitos humanos com a matriz e como plataforma para testes de novos fármacos. Existe uma demanda crescente para a utilização de pele e derme reconstruídas em laboratório, em ensaios in vitro de citotoxicidade, viabilidade celular, crescimento celular, irritabilidade e avaliação dos constituintes da matriz extracelular. Caracterizamos, em equivalente dérmico, alguns mecanismos de viabilidade e invasão de melanoma metastático humano quando na presença da matriz, a fim de ampliar o conhecimento a respeito de novas terapias contra o melanoma e entender os mecanismos que favorecem seu potencial invasivo, mimetizando com mais fidelidade o que ocorre in vivo. Através da validação deste modelo, constatamos que ele é essencial para resgatar a fisiopatologia do tumor, pois o melanoma, na presença de equivalente dérmico, torna-se capaz de evadir mecanismos de morte e aumentar a secreção de metaproteinases e citocinas que favorecerão a evolução tumoral. Avaliamos também as propriedades antineoplásicas do ácido clorogênico, que já foram relatadas em um grande número de tumores, porém os mecanismos que levam à sua ação antitumoral ainda não foram bem elucidados. Diante dos trabalhos enfatizando o efeito quimioprotetor dos polifenóis, referentes à sua ação antioxidante em células neoplásicas e com potencial metastático, não há na literatura estudos que comprovem a eficácia do ácido clorogênico sobre células de melanoma metastático humano. Portanto, este estudo visou recriar a estrutura dérmica in vitro e, a partir disso, comparar a resposta de fármacos em células de melanoma cultivada em equivalente dérmico, a fim de avaliar se há modulação diferencial nesse substrato, sugerindo, portanto, um protocolo mais eficaz para a prospecção de fármacos antimelanoma. The microenvironment reconstruction models are useful for investigating the biological properties of human melanocytes onto the matrix and as platform for testing new drugs. There is a growing demand for the use of reconstructed skin and dermis in the laboratory for in vitro assays of cytotoxicity, viability, cell growth, irritability, and evaluation of the extracellular matrix. We characterize in dermal equivalent some mechanisms for cell viability and invasion of human metastatic melanoma in the presence of matrix, the order to increase knowledge about new therapies against melanoma and to understand the mechanisms that favor its invasive potential, to more closely mimic what occurs in vivo. By means of this model, we find that it is essential to rescue the tumor physiopathology as melanoma, in the presence of dermal equivalent, it is able to evade death mechanisms and increase the expression of metalloproteinases and cytokines which favor the tumor evolution. We also evaluated the antineoplastic properties of chlorogenic acid, that have been reported in a large number of tumors, but the mechanisms that lead to its antitumor action has not been well elucidated. Before the work emphasizing the chemoprotective effect of polyphenols related to its antioxidant action in neoplastic cells and with metastatic potential, there is no literature studies confirming the effectiveness of chlorogenic acid on human metastatic melanoma cells. Therefore, this study aims to rebuild the dermal structure in vitro, and from this, to compare the response to drugs in melanoma cells dermal equivalent cultured in order to evaluate whether modulation differential on the substrate, thus suggesting a protocol more effective for prospecting antimelanoma drugs.
- Published
- 2015
41. Artificial skin in perspective: concepts and applications
- Author
-
Laura Beatriz da Silva Cardeal, Silvya Stuchi Maria-Engler, Maria S. Soengas, Manoela Tiago, Carla Abdo Brohem, and Silvia Berlanga de Moraes Barros
- Subjects
integumentary system ,Human skin ,Dermatology ,Anatomy ,Absorption (skin) ,Biology ,Matrix (biology) ,General Biochemistry, Genetics and Molecular Biology ,Artificial skin ,Cell biology ,medicine.anatomical_structure ,Oncology ,Tissue engineering ,Dermis ,medicine ,Epidermis ,Animal testing - Abstract
Skin, the largest organ of the human body, is organized into an elaborate layered structure consisting mainly of the outermost epidermis and the underlying dermis. A subcutaneous adipose-storing hypodermis layer and various appendages such as hair follicles, sweat glands, sebaceous glands, nerves, lymphatics, and blood vessels are also present in the skin. These multiple components of the skin ensure survival by carrying out critical functions such as protection, thermoregulation, excretion, absorption, metabolic functions, sensation, evaporation management, and aesthetics. The study of how these biological functions are performed is critical to our understanding of basic skin biology such as regulation of pigmentation and wound repair. Impairment of any of these functions may lead to pathogenic alterations, including skin cancers. Therefore, the development of genetically controlled and well characterized skin models can have important implications, not only for scientists and physicians, but also for manufacturers, consumers, governing regulatory boards and animal welfare organizations. As cells making up human skin tissue grow within an organized three-dimensional (3D) matrix surrounded by neighboring cells, standard monolayer (2D) cell cultures do not recapitulate the physiological architecture of the skin. Several types of human skin recombinants, also called artificial skin, that provide this critical 3D structure have now been reconstructed in vitro. This review contemplates the use of these organotypic skin models in different applications, including substitutes to animal testing.
- Published
- 2010
42. Abstract 105: CADM1 is a TWIST1-regulated suppressor of melanoma invasion and survival
- Author
-
Dan A. Erkes, Inna Chervoneva, Edward J. Hartsough, Sheera Rosenbaum, Curtis H. Kugel, Michele B. Weiss, Shea A. Heilman, Timothy J. Purwin, Andrew E. Aplin, and Manoela Tiago
- Subjects
Cancer Research ,Oncology ,law ,Melanoma ,Cancer research ,medicine ,Suppressor ,Biology ,medicine.disease ,law.invention - Abstract
Metastatic melanoma is the deadliest form of skin cancer; however, patients diagnosed and treated prior to metastatic dissemination have a good prognosis. The transcription factor, TWIST1 has been implicated in enhancing the migration and invasion of melanoma cells but the range of TWIST1-regulated targets is poorly described. In this study, we performed expression profiling to identify the TWIST1-regulated transcriptome. Gene ontology pathway analysis revealed that TWIST1 and epithelial to mesenchymal transition (EMT) were inversely correlated with levels of cell adhesion molecule 1 (CADM1). Chromatin immunoprecipitation (ChIP) studies and promoter assays demonstrated that TWIST1 physically interacts with the CADM1 promoter, suggesting TWIST1 directly represses CADM1 levels. Modulation of CADM1 resulted in significant effects on the migration and invasion of melanoma cells. In addition, elevated CADM1 elicited cell death in non-adherent conditions, an effect that could not be rescued with a pan-caspase inhibitor. Analyses suggest that CADM1 directed non-adherent cell death is associated with loss of mitochondrial membrane potential and subsequent failure of oxidative phosphorylation pathways. Furthermore, clinical data from TCGA indicates that CADM1 expression is correlated with better overall survival in patients. Together, these data suggest that CADM1 exerts tumor suppressive functions in melanoma by reducing invasive potential and may be a biomarker for improved survival of melanoma patients. Citation Format: Edward J. Hartsough, Michele B. Weiss, Shea A. Heilman, Timothy J. Purwin, Curtis H. Kugel, Sheera R. Rosenbaum, Dan A. Erkes, Manoela Tiago, Inna Chervoneva, Andrew E. Aplin. CADM1 is a TWIST1-regulated suppressor of melanoma invasion and survival [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 105.
- Published
- 2018
43. Basic Red 51, a permitted semi-permanent hair dye, is cytotoxic to human skin cells: studies in monolayer and 3D skin model using human keratinocytes (HaCaT)
- Author
-
Fernanda Faião-Flores, Thalita B. Zanoni, Silvya Stuchi Maria-Engler, Manoela Tiago, Danielle Palma de Oliveira, Silvia Berlanga de Moraes Barros, Aalt Bast, Geja J. Hageman, Farmacologie en Toxicologie, RS: NUTRIM - R3 - Chronic inflammatory disease and wasting, and RS: CARIM - R3 - Vascular biology
- Subjects
Keratinocytes ,Stereochemistry ,Cell Survival ,Hair Dyes ,Human skin ,Caspase 3 ,Apoptosis ,Toxicology ,Cell Line ,Necrosis ,Humans ,Cytotoxicity ,Carcinogen ,chemistry.chemical_classification ,Reactive oxygen species ,integumentary system ,Epidermis (botany) ,Dose-Response Relationship, Drug ,Molecular Structure ,Chemistry ,General Medicine ,Molecular biology ,TOXICOLOGIA ,HaCaT ,Azo Compounds - Abstract
The use of hair dyes is closely associated with the increase of cancer, inflammation and other skin disorders. The recognition that human skin is not an impermeable barrier indicates that there is the possibility of human systemic exposure. The carcinogenic potential of hair dye ingredients has attracted the attention of toxicologists for many decades, mainly due to the fact that some ingredients belong to the large chemical family of aromatic amines. Herein, we investigated the cytotoxicity of Basic Red 51 (BR51) in immortalized human keratinocytes (HaCaT). BR51 is a temporary hair dye that belongs to the azo group (N N); the cleavage of this bond may result in the release of toxic aromatic amines. The half maximal effective concentration (EC 50 ) in HaCaT cells is 13 μg/mL. BR51 induced a significant decrease on expression of p21 in a dose dependent manner. p53 was not affected, whereas BR51 decreased procaspase 8 and cleaved procaspase 9. These results proved that caspase 3 is fully involved in BR51-induced apoptosis. The dye was also able to stop this cell cycle on G2 in sub-toxic doses. Moreover, we reconstructed a 3D artificial epidermis using HaCaT cells; using this model, we observed that BR51 induced cell injury and cells were undergoing apoptosis, considering the fragmented nuclei. Subsequently, BR51 induced reactive oxygen species (ROS) leading to an increase on the levels of 8-oxo-dG. In conclusion, we provide strong evidence that consumer and/or professional exposure to BR51 poses risk to human health.
- Published
- 2014
44. Proteasome inhibition and ROS generation by 4-nerolidylcatechol induces melanoma cell death
- Author
-
Carla A, Brohem, Renato R, Massaro, Manoela, Tiago, Camila E, Marinho, Miriam G, Jasiulionis, Rebeca L, de Almeida, Diogo P, Rivelli, Renata C, Albuquerque, Tiago F, de Oliveira, Ana P, de Melo Loureiro, Sabrina, Okada, María S, Soengas, Silvia B, de Moraes Barros, and Silvya S, Maria-Engler
- Subjects
Skin Neoplasms ,Cell Death ,Catechols ,Drug Evaluation, Preclinical ,Antineoplastic Agents ,Apoptosis ,DNA Fragmentation ,DNA, Neoplasm ,Free Radical Scavengers ,Models, Biological ,Antioxidants ,Tumor Cells, Cultured ,Humans ,Protease Inhibitors ,Reactive Oxygen Species ,Melanoma ,Proteasome Inhibitors - Abstract
Induction of apoptotic cell death in response to chemotherapy and other external stimuli has proved extremely difficult in melanoma, leading to tumor progression, metastasis formation and resistance to therapy. A promising approach for cancer chemotherapy is the inhibition of proteasomal activity, as the half-life of the majority of cellular proteins is under proteasomal control and inhibitors have been shown to induce cell death programs in a wide variety of tumor cell types. 4-Nerolidylcatechol (4-NC) is a potent antioxidant whose cytotoxic potential has already been demonstrated in melanoma tumor cell lines. Furthermore, 4-NC was able to induce the accumulation of ubiquitinated proteins, including classic targets of this process such as Mcl-1. As shown for other proteasomal inhibitors in melanoma, the cytotoxic action of 4-NC is time-dependent upon the pro-apoptotic protein Noxa, which is able to bind and neutralize Mcl-1. We demonstrate the role of 4-NC as a potent inducer of ROS and p53. The use of an artificial skin model containing melanoma also provided evidence that 4-NC prevented melanoma proliferation in a 3D model that more closely resembles normal human skin.
- Published
- 2012
45. Artificial skin in perspective: concepts and applications
- Author
-
Carla A, Brohem, Laura B da Silva, Cardeal, Manoela, Tiago, María S, Soengas, Silvia B de Moraes, Barros, and Silvya S, Maria-Engler
- Subjects
Skin, Artificial ,integumentary system ,Tissue Engineering ,Animals ,Humans ,Models, Biological ,Article ,Skin - Abstract
Skin, the largest organ of the human body, is organized into an elaborate layered structure consisting mainly of the outermost epidermis and the underlying dermis. A subcutaneous adipose-storing hypodermis layer and various appendages such as hair follicles, sweat glands, sebaceous glands, nerves, lymphatics and blood vessels are also present in the skin. These multiple components of the skin ensure survival by providing critical functions in protection, thermoregulation, excretion, absorption, metabolic functions, sensation, evaporation management and aesthetics. The study of how these biological functions are performed is critical in our understanding of basic skin biology, such as regulation of pigmentation and wound repair. Impairment of any of these functions may lead to pathogenic alterations, including skin cancers. Therefore, the development of genetically controlled and well-characterized skin models can have important implications, not only for scientists and physicians, but also for manufacturers, consumers, governing regulatory boards and animal welfare organizations. Since cells making up human skin tissue grow within an organized three dimensional (3D) matrix continually surrounded by neighboring cells, standard monolayer (2D) cell cultures do not recapitulate the physiological architecture of the skin. Several types of human skin recombinants, also called artificial skin, that provide this critical 3-D structure, have now been reconstructed in vitro. This review contemplates the use of these organotypic skin models in different applications, including substitutes to animal testing.
- Published
- 2010
46. A Natural Bacterial-Derived Product, the Metalloprotease Arazyme, Inhibits Metastatic Murine Melanoma by Inducing MMP-8 Cross-Reactive Antibodies
- Author
-
Manoela Tiago, Maria A. Juliano, Alisson L. Matsuo, Thaysa Paschoalin, Jorge Augusto Borin Scutti, Filipe M. de Melo, Elaine G. Rodrigues, Luis Silva, Luiz Juliano, Amanda Campelo L Melo, Priscila Henriques da Silva, Carla A. Ferreira-Guimaraes, Adriana K. Carmona, Luiz R. Travassos, and Felipe V. Pereira
- Subjects
Melanomas ,Male ,Skin Neoplasms ,Serratia ,Hydrolases ,Cell ,Cancer Treatment ,Melanoma, Experimental ,lcsh:Medicine ,Biochemistry ,Mice ,Medicine and Health Sciences ,Cytotoxic T cell ,Neoplasm Metastasis ,lcsh:Science ,Skin Tumors ,Metalloproteinase ,Multidisciplinary ,biology ,Melanoma ,Flow Cytometry ,Enzymes ,Matrix Metalloproteinase 8 ,medicine.anatomical_structure ,Oncology ,Antibody ,Research Article ,Immunology ,Enzyme-Linked Immunosorbent Assay ,Dermatology ,Cross Reactions ,Real-Time Polymerase Chain Reaction ,Antibody Therapy ,Complementary and Alternative Medicine ,In vivo ,medicine ,Animals ,Collagenases ,DNA Primers ,Base Sequence ,lcsh:R ,CD44 ,Biology and Life Sciences ,Cancers and Neoplasms ,medicine.disease ,Molecular biology ,In vitro ,Mice, Inbred C57BL ,Enzymology ,Metalloproteases ,biology.protein ,Cancer research ,lcsh:Q ,Clinical Immunology - Abstract
The increased incidence, high rates of mortality and few effective means of treatment of malignant melanoma, stimulate the search for new anti-tumor agents and therapeutic targets to control this deadly metastatic disease. In the present work the antitumor effect of arazyme, a natural bacterial-derived metalloprotease secreted by Serratia proteomaculans, was investigated. Arazyme significantly reduced the number of pulmonary metastatic nodules after intravenous inoculation of B16F10 melanoma cells in syngeneic mice. In vitro, the enzyme showed a dose-dependent cytostatic effect in human and murine tumor cells, and this effect was associated to the proteolytic activity of arazyme, reducing the CD44 expression at the cell surface, and also reducing in vitro adhesion and in vitro/in vivo invasion of these cells. Arazyme treatment or immunization induced the production of protease-specific IgG that cross-reacted with melanoma MMP-8. In vitro, this antibody was cytotoxic to tumor cells, an effect increased by complement. In vivo, arazyme-specific IgG inhibited melanoma lung metastasis. We suggest that the antitumor activity of arazyme in a preclinical model may be due to a direct cytostatic activity of the protease in combination with the elicited anti-protease antibody, which cross-reacts with MMP-8 produced by tumor cells. Our results show that the bacterial metalloprotease arazyme is a promising novel antitumor chemotherapeutic agent.
- Published
- 2014
47. Apoptosis through Bcl-2/Bax and Cleaved Caspase Up-Regulation in Melanoma Treated by Boron Neutron Capture Therapy
- Author
-
Ricardo Rodrigues Giorgi, Vera Luiza Capelozzi, Paulo Rogério Pinto Coelho, Silvya Stuchi Maria-Engler, Fernanda Faião-Flores, Manoela Tiago, Durvanei Augusto Maria, and J. D. T. Arruda-Neto
- Subjects
Melanomas ,Skin Neoplasms ,Cell cycle checkpoint ,Cancer Treatment ,Melanoma, Experimental ,lcsh:Medicine ,Apoptosis ,Receptors, Tumor Necrosis Factor ,Extracellular matrix ,Molecular Cell Biology ,Basic Cancer Research ,Linear Energy Transfer ,lcsh:Science ,Skin Tumors ,Caspase ,bcl-2-Associated X Protein ,Multidisciplinary ,Cell Death ,biology ,Chemistry ,Malignant Melanoma ,Melanoma ,Flow Cytometry ,Immunohistochemistry ,Extracellular Matrix ,Gene Expression Regulation, Neoplastic ,Oncology ,Proto-Oncogene Proteins c-bcl-2 ,Caspases ,Medicine ,Melanocytes ,Collagen ,Radiology ,Research Article ,inorganic chemicals ,Programmed cell death ,Radiation Biophysics ,Blotting, Western ,Biophysics ,Radiation Therapy ,Malignant Skin Neoplasms ,Boron Neutron Capture Therapy ,Dermatology ,Real-Time Polymerase Chain Reaction ,Bcl-2-associated X protein ,Microscopy, Electron, Transmission ,Cell Line, Tumor ,medicine ,Humans ,Biology ,HSP47 Heat-Shock Proteins ,Cell Proliferation ,DNA Primers ,Analysis of Variance ,Radiotherapy ,Cell growth ,lcsh:R ,Cancers and Neoplasms ,medicine.disease ,Molecular biology ,biology.protein ,Cancer research ,lcsh:Q ,Nuclear Medicine ,Radiopharmaceuticals - Abstract
Boron neutron capture therapy (BNCT) is a binary treatment involving selective accumulation of boron carriers in a tumor followed by irradiation with a thermal or epithermal neutron beam. The neutron capture reaction with a boron-10 nucleus yields high linear energy transfer (LET) particles, alpha and (7)Li, with a range of 5 to 9 µm. These particles can only travel very short distances and release their damaging energy directly into the cells containing the boron compound. We aimed to evaluate proliferation, apoptosis and extracellular matrix (ECM) modifications of B16F10 melanoma and normal human melanocytes after BNCT. The amounts of soluble collagen and Hsp47, indicating collagen synthesis in the ECM, as well as the cellular markers of apoptosis, were investigated. BNCT decreased proliferation, altered the ECM by decreasing collagen synthesis and induced apoptosis by regulating Bcl-2/Bax in melanoma. Additionally, BNCT also increased the levels of TNF receptor and the cleaved caspases 3, 7, 8 and 9 in melanoma. These results suggest that multiple pathways related to cell death and cell cycle arrest are involved in the treatment of melanoma by BNCT.
- Published
- 2013
48. Prospecção de novos fármacos para melanoma em equivalente dérmico
- Author
-
Santos, Manoela Tiago dos, primary
- Full Text
- View/download PDF
49. Mecanismos de regulação epigenética e heterogeneidade tumoral clonal em melanoma metastático humano envolvendo gene RECK
- Author
-
Santos, Manoela Tiago dos, primary
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.